keyword
https://read.qxmd.com/read/36261393/influence-of-serum-vitamin-d-level-in-the-response-of-actinic-keratosis-to-ingenol-mebutate
#21
JOURNAL ARTICLE
Ricardo Moreno-Alonso de Celada, Tamara Gracia-Cazaña, Laura Najera-Botello, Paulina Cerro-Muñoz, Angeles Juarranz, Salvador Gonzalez, Yolanda Gilaberte
Vitamin D (VD) serum levels, and keratinocytic basal expression of vitamin D receptor (VDR) before treatment of actinic keratoses (AK) have been previously reported as possible biomarkers of the response of AK to treatments. We intended to evaluate the association between these and other serum and immunohistochemical parameters with the response of AK to treatment with topical ingenol mebutate (IM). Twenty-five patients with AK on the head were treated with topical IM 0.015% gel once daily for 3 days. Biopsies were taken at baseline and 6 weeks after treatment...
October 19, 2022: Dermatologic Therapy
https://read.qxmd.com/read/36232651/topical-treatment-of-actinic-keratosis-and-metalloproteinase-expression-a-clinico-pathological-retrospective-study
#22
JOURNAL ARTICLE
Elena Campione, Monia Di Prete, Cosimo Di Raimondo, Gaetana Costanza, Vincenzo Palumbo, Virginia Garofalo, Sara Mazzilli, Chiara Franceschini, Emi Dika, Luca Bianchi, Augusto Orlandi
Actinic keratosis is an intraepithelial proliferation of atypical keratinocytes that could progress into invasive squamous cell carcinoma. Most evidence suggests an important role of the dermal matrix metalloproteinases in the progression of atypical skin epithelial lesions. We evaluated the clinical efficacy of three different therapeutic modalities (a medical device containing 0.8% piroxicam cream and 50+ sunscreen, photodynamic therapy, and ingenol mebutate gel) to treat suspicious actinic keratoses, which were biopsied for histopathological examination and then analyzed for the expression of matrix metalloproteinases by immunohistochemistry...
September 26, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/35724704/repurposing-of-ingenol-mebutate-for-treating-human-colorectal-cancer-by-targeting-s100-calcium-binding-protein-a4-s100a4
#23
JOURNAL ARTICLE
Yao-Yu Hsieh, Ya-Wen Cheng, Po-Li Wei, Pei-Ming Yang
Colorectal cancer (CRC) is the world's second most common cause of cancer-related death. Novel treatments are still urgently needed. S100 calcium-binding protein A4 (S100A4) was demonstrated to be an anticancer therapeutic target. Herein, we found that higher S100A4 expression was associated with a poorer prognosis in publicly available cohorts and a Taiwanese CRC patient cohort. To identify repurposed S100A4 inhibitors, we mined the Connectivity Map (CMap) database for clinical drugs mimicking the S100A4-knockdown gene signature...
June 18, 2022: Toxicology and Applied Pharmacology
https://read.qxmd.com/read/35555684/structural-basis-of-agonist-capture-by-regulatory-c1-domain-of-pkc
#24
JOURNAL ARTICLE
Sachin S Katti, Inna V Krieger, James C Sacchettini, Tatyana I Igumenova
Diacylglycerol (DAG)-sensing C1 domains of Protein kinase C (PKC) isoforms are targets for therapeutic intervention in cancers, neurodegenerative disorders, and HIV latency reversal. High-resolution structural information on the C1 domains complexed to DAG or exogenous PKC agonists remained elusive for nearly 3 decades. This is attributed to the extreme hydrophobicity of the C1 complexes and the need to create an optimal membrane-mimicking environment to facilitate the complex formation and crystallization...
May 2022: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://read.qxmd.com/read/35498090/systematic-characterization-of-metabolic-profiles-of-ingenol-in-rats-by-uplc-q-tof-ms-and-nmr-in-combination-with-microbial-biotransformation
#25
JOURNAL ARTICLE
Si-Jia Xiao, Shan-Shan Li, Bin Xie, Wei Chen, Xi-Ke Xu, Xian-Peng Zu, Yun-Heng Shen
Ingenol, as the precursor of the marketed drug ingenol mebutate, has been proven to have a variety of bioactivities. The purpose of this study was to identify the metabolites of ingenol using ultra-performance liquid chromatography-quadrupole time-of-flight-mass spectrometry (UPLC-Q/TOF-MS) combined with UNIFI software. Plasma, urine and fecal samples of rats were obtained and analyzed. A total of 18 metabolites were detected and identified in rat, including five phase II metabolites (M14-M18). Moreover, as microbial biotransformation is helpful to obtain sufficient reference standards of metabolites, the co-culture of ingenol with the fungus Cunninghamella elegans bio-110930 was also studied and yielded 4 phase I metabolites, in which reference standards of three metabolites were further obtained by preparative scale biotransformation...
November 23, 2021: RSC Advances
https://read.qxmd.com/read/35475852/risk-of-invasive-cutaneous-squamous-cell-carcinoma-after-different-treatments-for-actinic-keratosis-a-secondary-analysis-of-a-randomized-clinical-trial
#26
RANDOMIZED CONTROLLED TRIAL
Shima Ahmady, Maud H E Jansen, Patty J Nelemans, Janneke P H M Kessels, Aimee H M M Arits, Michette J M de Rooij, Brigitte A B Essers, Patricia J F Quaedvlieg, Nicole W J Kelleners-Smeets, Klara Mosterd
IMPORTANCE: Treatment of actinic keratosis (AK) aims to prevent cutaneous squamous cell carcinoma (cSCC). However, whether AK can progress into invasive cSCC is a matter of debate, and little is known about the effect of treatment on preventing cSCC. OBJECTIVES: To evaluate the risk of invasive cSCC and factors that may contribute to increased risk in patients with multiple AKs. DESIGN, SETTING, AND PARTICIPANTS: In this secondary analysis of a multicenter randomized clinical trial, 624 patients with a minimum of 5 AKs within an area of 25 to 100 cm2 on the head were recruited from the Department of Dermatology of 4 hospitals in the Netherlands...
June 1, 2022: JAMA Dermatology
https://read.qxmd.com/read/35465033/approaches-to-field-therapy-for-actinic-keratoses-relating-clinical-trial-results-to-real-world-practice-a-commentary
#27
EDITORIAL
David M Pariser
There have been multiple direct and indirect comparison studies evaluating different field therapies used in the treatment of actinic keratosis (AK). A recent clinical trial directly compared 5% fluorouracil (5-FU), imiquimod, ingenol mebutate, and methyl aminolevulinate photodynamic therapy (MAL-PDT), reporting that 5-FU was superior to the other treatments in achieving sustained clearance of 75 percent or greater of AK lesions compared to baseline. In this commentary, the author reviews and discusses the methods and results of this comparison study and propose these results are limited by a number of factors, such as the selected primary % clearance endpoint, grade range of included AKs, and treatments included in the comparison, when considered in the context of other clinical and real-world comparison studies evaluating AK field therapies...
April 2022: Journal of Clinical and Aesthetic Dermatology
https://read.qxmd.com/read/35329979/comparative-efficacy-and-safety-of-tirbanibulin-for-actinic-keratosis-of-the-face-and-scalp-in-europe-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials
#28
JOURNAL ARTICLE
Markus V Heppt, Igor Dykukha, Sara Graziadio, Rafael Salido-Vallejo, Matt Chapman-Rounds, Mary Edwards
Actinic keratosis (AK) is a chronic skin condition that may progress to cutaneous squamous cell carcinoma. We conducted a systematic review of efficacy and safety for key treatments for AK of the face and scalp, including the novel 5-day tirbanibulin 1% ointment. MEDLINE, PubMed, Embase, Cochrane Library, clinical trial registries and regulatory body websites were searched. The review included 46 studies, of which 35 studies included interventions commonly used in Europe and were sufficiently homogenous to inform a Bayesian network meta-analysis of complete clearance against topical placebo or vehicle...
March 16, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/35068520/a-case-of-new-onset-pemphigus-erythematosus-after-topical-application-of-ingenol-mebutate
#29
JOURNAL ARTICLE
Hee Joo Yang, Woo Jin Lee, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Jee Ho Choi, Young Jae Kim
No abstract text is available yet for this article.
September 2021: Indian Journal of Dermatology
https://read.qxmd.com/read/34877845/porokeratosis-an-enigma-beginning-to-unravel
#30
REVIEW
Anupam Das, Biju Vasudevan, Ankur Talwar
Porokeratosis is a keratinization disorder with unclear etiopathogenesis, varied clinical presentation and characteristic histopathology, and is usually unresponsive to current therapeutic options. Until now, it was considered to be a clonal disorder with immunity, ultra violet radiation and other factors playing important roles in etiopathogenesis. It is now known that abnormalities in the mevalonate pathway are responsible for this clonal keratinization abnormality. New variants of porokeratosis like eruptive bullous, pruriginous, lichen planus like, follicular variants and porokeratoma have been described...
May 2022: Indian Journal of Dermatology, Venereology and Leprology
https://read.qxmd.com/read/34636523/individual-article-safety-and-tolerability-of-topical-agents-for-actinic-keratosis-a-systematic-review-of-phase-3-clinical-trials
#31
JOURNAL ARTICLE
Jeffrey R Rajkumar, April W Armstrong, Leon H Kircik
BACKGROUND: Topical agents for actinic keratosis (AK), along with cryotherapy and phototherapy, are the most commonly used therapies for areas of skin with multiple AKs. Multiple options for the topical treatment of AK exist; newer therapies aim to balance efficacy with an acceptable safety and tolerability profile for the patient. OBJECTIVE: To describe the safety and tolerability of FDA-approved topical agents for the treatment of AK. METHODS: A systematic review of phase III clinical trials of topical agents for AK available on PubMed and clinicaltrials...
October 1, 2021: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/34526198/squamous-cell-carcinoma-in-situ-review-of-therapeutic-options-with-emphasis-on-treatment-of-tumors-of-the-lower-extremity
#32
JOURNAL ARTICLE
Nicole Vesely, Paula Beers, Sailesh Konda, Kiran Motaparthi
Squamous cell carcinoma in situ (SCCis), also known as Bowen's disease, is a common superficial malignancy of the skin. Treatment of SCCis is important to prevent invasion into the dermis as well as metastases. Treatment of SCCis may be challenging based on the location of the tumor, advanced age, immunosuppression, medical comorbidities, or desire for noninvasive treatment. SCCis on the lower leg can be particularly challenging to treat due to poor wound healing in the setting of suboptimal circulation. This report reviews the evidence for various treatment options of SCCis, including their advantages, disadvantages, and efficacy, with an emphasis on treatment of SCCis of the lower extremity...
2021: Skinmed
https://read.qxmd.com/read/34409369/topical-treatments-for-early-stage-mycosis-fungoides-using-grading-recommendations-assessment-development-and-evaluation-grade-criteria-a-systematic-review
#33
REVIEW
Ebba Wennberg, Phillip Q Richards, Paul A Bain, Victor Huang, Sydney D Sullivan, Emanual M Maverakis, Gabriel E Molina, Peggy A Wu
BACKGROUND: Mycosis fungoides (MF) is a cutaneous lymphoma; most patients present with early, skin-limited disease and are managed by dermatologists. OBJECTIVE: The purpose of this study was to systematically review and assess the evidence on topical treatments for early-stage (IA, IB, IIA) MF. METHODS: We performed a literature search via MEDLINE, Embase, Web of Science, and Cochrane databases. Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria were used to assess the certainty of the data...
June 2021: JAAD international
https://read.qxmd.com/read/34198524/ingol-and-ingenol-type-diterpenes-from-euphorbia-trigona-miller-with-keratinocyte-inhibitory-activity
#34
JOURNAL ARTICLE
Reham Hammadi, Norbert Kúsz, Csilla Zsuzsanna Dávid, Zoltán Behány, László Papp, Lajos Kemény, Judit Hohmann, Lóránt Lakatos, Andrea Vasas
Ingenol mebutate, isolated from Euphorbia peplus , is an ingenane-type diterpenoid, primarily used for the topical treatment of actinic keratosis, a premalignant skin condition. The aim of our work was to investigate other Euphorbia species to find structurally similar diterpenes that can be used as alternatives to ingenol mebutate. Pharmacological investigation of Euphorbia candelabrum , Euphorbia cotinifolia , Euphorbia ramipressa , and Euphorbia trigona revealed the potent keratinocyte (HPV-Ker cell line) inhibitory activity of these spurge species...
June 14, 2021: Plants (Basel, Switzerland)
https://read.qxmd.com/read/34052139/rf-herpes-zoster-triggered-by-ingenol-mebutate-gel-first-european-case-report
#35
JOURNAL ARTICLE
M Garayar Cantero, E Manrique-Silva, E Godoy-Gijón
No abstract text is available yet for this article.
May 14, 2021: Actas dermo-sifiliográficas
https://read.qxmd.com/read/33976100/tirbanibulin-1-ointment-klisyri-for-actinic-keratosis
#36
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 3, 2021: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/33922439/targeting-cutaneous-t-cell-lymphoma-cells-by-ingenol-mebutate-pep005-correlates-with-pkc%C3%AE-activation-ros-induction-as-well-as-downregulation-of-xiap-and-c-flip
#37
JOURNAL ARTICLE
Uly Sumarni, Ulrich Reidel, Jürgen Eberle
New therapeutic strategies are needed for cutaneous T-cell lymphoma (CTCL), and the plant extract ingenol mebutate (PEP005) may be considered. PEP005 has been approved for actinic keratosis, and proapoptotic activities were described in different cancer cells. Here, we aimed to investigate its efficacy in four CTCL cell lines and its mode of action. While HuT-78 and HH responded with induced apoptosis as well as with loss of cell viability and cell proliferation, MyLa and SeAx remained resistant. Interestingly, both sensitive and resistant cells showed caspase-8 activation and enhanced levels of reactive oxygen species (ROS), while final caspase-3 activation was restricted to sensitive cells...
April 23, 2021: Cells
https://read.qxmd.com/read/33872195/erosive-pustular-dermatosis-of-the-scalp-clinicopathological-correlation-leading-to-a-definition-of-diagnostic-criteria
#38
JOURNAL ARTICLE
Robin Reschke, Sonja Grunewald, Uwe Paasch, Marco Averbeck, Jan C Simon, Tino Wetzig
INTRODUCTION: Erosive pustular dermatosis of the scalp (EPDS) is frequently misdiagnosed as epithelial tumor or trauma. To the authors' knowledge, no international guidelines or consistent recommendations for treatment of EPDS exist, and histological findings often are labeled as nonspecific. OBJECTIVE: This study aimed to identify clinical and histological characteristics unique to EPDS to aid diagnosis. MATERIALS AND METHODS: The biopsies of 21 patients (age range, 73-90 years) with EPDS and who were diagnosed and treated at the Department of Dermatology at University of Leipzig Medical Center and the Asklepios Medical Center, Weißenfels, Germany, were reevaluated by dermatopathologists...
April 7, 2021: Wounds: a Compendium of Clinical Research and Practice
https://read.qxmd.com/read/33834933/safety-of-topical-interventions-for-the-treatment-of-actinic-keratosis
#39
REVIEW
Elias A T Koch, Anja Wessely, Theresa Steeb, Carola Berking, Markus V Heppt
Introduction: Actinic keratosis (AK) are proliferations of atypical keratinocytes that may eventually progress to cutaneous squamous cell carcinoma. Therefore, AK requires consequent and early treatment. Areas covered: A variety of effective approaches is currently available for the clearance of AK. These interventions may be applied either in a lesion-directed or field-directed mode as AK can occur as single or multiple lesions. Field-directed approaches typically comprise topical drug-mediated interventions which aim at eliminating all visible lesions and also at clearing subclinical changes of the actinically damaged field...
July 2021: Expert Opinion on Drug Safety
https://read.qxmd.com/read/33794325/sequential-receptor-mediated-mixed-charge-nanomedicine-to-target-pancreatic-cancer-inducing-immunogenic-cell-death-and-reshaping-the-tumor-microenvironment
#40
JOURNAL ARTICLE
Jingmin Shen, Chao Sun, Zhicheng Wang, Zhijie Chu, Chengcheng Liu, Xuelian Xu, Ming Xia, Miaoqing Zhao, Cheng Wang
Pancreatic cancer (PC) is an aggressive form of cancer with dense stroma and immune-suppressive microenvironment, which are the major barriers for treatment. To address such barriers, this study aimed to develop a sequential receptor-mediated mixed-charge targeted delivery system for PC based on 2-(3-((S)-5-amino-1-carboxypentyl)-ureido) pentanedioate (ACUPA- ) and triphenylphosphonium (TPP+ ) modified nanomicelles containing ingenol-3-mebutate (I3A), which was named ACUPA- /TPP+ -I3A or ACUPA/TPP-I3A. ACUPA/TPP-I3A induced immunogenic cell death (ICD), which significantly increased the number of tumor-infiltrating T lymphocytes, activated adaptive immunity, and achieved superior survival time...
March 29, 2021: International Journal of Pharmaceutics
keyword
keyword
51369
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.